SOPHiA GENETICS SA entered into an underwriting agreement with TD Securities (USA) LLC on June 16, 2026, for the offering and sale of 12,104,900 ordinary shares at $4.75 per share. The offering, which closed on June 18, 2026, generated approximately $57.5 million in gross proceeds. SOPHiA GENETICS SA is a healthcare technology company providing data-driven healthcare solutions through its software platform.
